Chargement en cours...
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
PURPOSE: Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL. PATIENTS AND METHODS: Fifty-nine adult patients (age 42 to 82 years) with...
Enregistré dans:
| Publié dans: | J Clin Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Clinical Oncology
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4878047/ https://ncbi.nlm.nih.gov/pubmed/23270003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.8623 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|